Nominations for Substances To Be Evaluated for Toxicological Profile Development, 53488-53489 [2023-16914]
Download as PDF
<![CDATA[
53488
Federal Register / Vol. 88, No. 151 / Tuesday, August 8, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
Background
The Patient Safety Act, 42 U.S.C.
299b–21 to 299b–26, and the related
Patient Safety Rule, 42 CFR part 3,
published in the Federal Register on
November 21, 2008 (73 FR 70732–
70814), establish a framework by which
individuals and entities that meet the
definition of provider in the Patient
Safety Rule may voluntarily report
information to PSOs listed by AHRQ, on
a privileged and confidential basis, for
the aggregation and analysis of patient
safety work product.
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
PSOs.
AHRQ has accepted a notification of
proposed voluntary relinquishment
from the American Physician Partners,
LLC PSO to voluntarily relinquish its
status as a PSO. Accordingly, the
American Physician Partners, LLC PSO,
P0223, was delisted effective at 12:00
Midnight ET (2400) on July 31, 2023.
American Physician Partners, LLC
PSO has patient safety work product
(PSWP) in its possession. The PSO will
meet the requirements of section
3.108(c)(2)(i) of the Patient Safety Rule
regarding notification to providers that
have reported to the PSO and of section
3.108(c)(2)(ii) regarding disposition of
PSWP consistent with section
3.108(b)(3). According to section
3.108(b)(3) of the Patient Safety Rule,
the PSO has 90 days from the effective
date of delisting and revocation to
complete the disposition of PSWP that
is currently in the PSO’s possession.
More information on PSOs can be
obtained through AHRQ’s PSO website
at https://www.pso.ahrq.gov.
VerDate Sep<11>2014
20:00 Aug 07, 2023
Jkt 259001
Dated: August 2, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–16895 Filed 8–7–23; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2023–0003]
Nominations for Substances To Be
Evaluated for Toxicological Profile
Development
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Agency for Toxic
Substances and Disease Registry
(ATSDR), within the Department of
Health and Human Services (HHS),
announces that it is soliciting
nominations of substances to be
evaluated for an upcoming set of
toxicological profiles. ATSDR is
opening a docket for the public to
submit nominations and provide
comment on which toxicological
profiles are developed next. Members of
the public, government agencies, or
private organizations may comment on
which substances they are concerned
about so that ATSDR may take this
information into consideration when
developing future toxicological profiles.
DATES: Written nominations and
comments must be received by
September 7, 2023.
ADDRESSES: You may submit
nominations, identified by Docket No.
ATSDR–2023–0003, by either of the
methods listed below. Do not submit
comments by email. ATSDR does not
accept comments by email.
• Federal eRulemaking Portal at
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Agency for Toxic Substances
and Disease Registry, Office of
Innovation and Analytics, 4770 Buford
Highway, Mail Stop S106–5, Atlanta,
GA 30341–3717. Attn: Docket No.
ATSDR–2023–0003.
Instructions: All submissions must
include the agency name and docket
number for this notice. All relevant
comments will be posted without
change to https://www.regulations.gov,
including any personal information
provided. Refer to the Submission of
Nominations section (below) for the
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
specific information required to be
included in a nomination. For access to
the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Farhana Rahman, Agency for Toxic
Substances and Disease Registry, Office
of Innovation and Analytics, 1600
Clifton Rd. NE, Mail Stop S106–5,
Atlanta, GA 30329–4027; Email:
ATSDRToxProfileFRNs@cdc.gov; Phone:
1–800–232–4636.
SUPPLEMENTARY INFORMATION: The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) [42
U.S.C. 9601 et seq.] amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) concerning hazardous substances
most commonly found at facilities on
the CERCLA National Priorities List
(NPL). Among these statutory
requirements is a mandate for the
Administrator of ATSDR to prepare
toxicological profiles for each substance
included on the Priority List of
Hazardous Substances, also known as
the Substance Priority list (SPL). This
list identifies 275 hazardous substances
found at NPL sites that ATSDR has
determined currently pose the most
significant potential threat to human
health. For more information on
ATSDR’s SPL, visit https://
www.atsdr.cdc.gov/SPL/.
Substances to be Evaluated for
Toxicological Profile Development
Each year, ATSDR develops a list of
substances to be considered for
toxicological profile development. The
nomination process includes
consideration of all substances on
ATSDR’s SPL, as well as other
substances nominated by the public.
Submission of Nominations for
Toxicological Profile Development
This notice invites public
nominations of substances for
toxicological profile development. If
nominating a substance that is not on
the SPL, please include the rationale for
the nomination and any supporting
data. ATSDR will evaluate data and
information associated with nominated
substances and will determine the final
list of substances to be chosen for
toxicological profile development.
Public Participation
Interested persons or organizations
are invited to participate by submitting
nominations for substances. These
E:\FR\FM\08AUN1.SGM
08AUN1
Federal Register / Vol. 88, No. 151 / Tuesday, August 8, 2023 / Notices
submissions may include written views
and data to support the nomination.
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. ATSDR will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign related to
substances being nominated. Do not
submit comments by email. ATSDR
does not accept comment by email.
Donata Green,
Acting Associate Director, Office of Policy,
Planning and Partnerships, Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2023–16914 Filed 8–7–23; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3446–PN]
Medicare and Medicaid Programs;
Application From the Community
Health Accreditation Program (CHAP)
for Continued Approval of Its Home
Health Agency Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice with comment.
AGENCY:
This proposed notice
acknowledges the receipt of an
application from Community Health
Accreditation Program (CHAP) for
continued recognition as a national
accrediting organization for home health
agencies (HHAs) that wish to participate
in the Medicare or Medicaid programs.
The statute requires that within 60 days
of receipt of an organization’s complete
application, the Centers for Medicare &
Medicaid Services (CMS) publish a
notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
20:00 Aug 07, 2023
Jkt 259001
provides at least a 30-day public
comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by
September 6, 2023.
ADDRESSES: In commenting, refer to file
code CMS–3446–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3446–PN, P.O. Box 8013,
Baltimore, MD 21244–8013.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3446–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Caecilia Blondiaux (410) 786–2190.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments.
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services from a Medicare-participating
home health agency (HHA), provided
certain requirements are met. Sections
1861(m) and (o), 1891 and 1895 of the
Social Security Act (the Act) establish
distinct criteria for an entity seeking
designation as an HHA. Regulations
concerning provider agreements are at
42 CFR part 489 and those pertaining to
activities relating to the survey and
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
53489
certification of facilities and other
entities are at 42 CFR part 488. The
regulations at 42 CFR parts 409 and 484
specify the conditions that an HHA
must meet to participate in the Medicare
program, the scope of covered services
and the conditions for Medicare
payment for home health care.
Generally, to enter into a provider
agreement with the Medicare program,
an HHA must first be certified by a state
survey agency as complying with the
conditions or requirements set forth in
42 CFR part 484 of our regulations.
Thereafter, the HHA is subject to regular
surveys by a state survey agency to
determine whether it continues to meet
these requirements.
However, there is an alternative to
surveys by state agencies. Section
1865(a)(1) of the Act provides that, if a
provider entity demonstrates through
accreditation by an approved national
accrediting organization that all
applicable Medicare conditions are met
or exceeded, we will deem those
provider entities as having met the
requirements. Accreditation by an
accrediting organization is voluntary
and is not required for Medicare
participation.
If an accrediting organization is
recognized by the Secretary of Health
and Human Services as having
standards for accreditation that meet or
exceed Medicare requirements, any
provider entity accredited by the
national accrediting body’s approved
program would be deemed to meet the
Medicare conditions. A national
accrediting organization applying for
CMS approval of their accreditation
program under 42 CFR part 488, subpart
A must provide CMS with reasonable
assurance that the accrediting
organization requires the accredited
provider entities to meet requirements
that are at least as stringent as the
Medicare conditions. Our regulations
concerning the approval of accrediting
organizations are set forth at § 488.5.
The regulations at § 488.5(e)(2)(i)
require accrediting organizations to
reapply for continued approval of their
accreditation program every 6 years or
sooner as determined by CMS.
The Community Health Accreditation
Program’s (CHAP’s) term of approval for
their HHA accreditation program
expires March 31, 2024.
II. Approval of Deeming Organization
Section 1865(a)(2) of the Act and our
regulations at § 488.5 require that our
findings concerning review and
approval of a national accrediting
organization’s requirements consider,
among other factors, the applying
accrediting organization’s requirements
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 88, Number 151 (Tuesday, August 8, 2023)]
[Notices]
[Pages 53488-53489]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-16914]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[Docket No. ATSDR-2023-0003]
Nominations for Substances To Be Evaluated for Toxicological
Profile Development
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR),
within the Department of Health and Human Services (HHS), announces
that it is soliciting nominations of substances to be evaluated for an
upcoming set of toxicological profiles. ATSDR is opening a docket for
the public to submit nominations and provide comment on which
toxicological profiles are developed next. Members of the public,
government agencies, or private organizations may comment on which
substances they are concerned about so that ATSDR may take this
information into consideration when developing future toxicological
profiles.
DATES: Written nominations and comments must be received by September
7, 2023.
ADDRESSES: You may submit nominations, identified by Docket No. ATSDR-
2023-0003, by either of the methods listed below. Do not submit
comments by email. ATSDR does not accept comments by email.
Federal eRulemaking Portal at https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Agency for Toxic Substances and Disease Registry,
Office of Innovation and Analytics, 4770 Buford Highway, Mail Stop
S106-5, Atlanta, GA 30341-3717. Attn: Docket No. ATSDR-2023-0003.
Instructions: All submissions must include the agency name and
docket number for this notice. All relevant comments will be posted
without change to https://www.regulations.gov, including any personal
information provided. Refer to the Submission of Nominations section
(below) for the specific information required to be included in a
nomination. For access to the docket to read background documents or
comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Farhana Rahman, Agency for Toxic
Substances and Disease Registry, Office of Innovation and Analytics,
1600 Clifton Rd. NE, Mail Stop S106-5, Atlanta, GA 30329-4027; Email:
[email protected]; Phone: 1-800-232-4636.
SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization
Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA
or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain
requirements for ATSDR and the U.S. Environmental Protection Agency
(EPA) concerning hazardous substances most commonly found at facilities
on the CERCLA National Priorities List (NPL). Among these statutory
requirements is a mandate for the Administrator of ATSDR to prepare
toxicological profiles for each substance included on the Priority List
of Hazardous Substances, also known as the Substance Priority list
(SPL). This list identifies 275 hazardous substances found at NPL sites
that ATSDR has determined currently pose the most significant potential
threat to human health. For more information on ATSDR's SPL, visit
https://www.atsdr.cdc.gov/SPL/.
Substances to be Evaluated for Toxicological Profile Development
Each year, ATSDR develops a list of substances to be considered for
toxicological profile development. The nomination process includes
consideration of all substances on ATSDR's SPL, as well as other
substances nominated by the public.
Submission of Nominations for Toxicological Profile Development
This notice invites public nominations of substances for
toxicological profile development. If nominating a substance that is
not on the SPL, please include the rationale for the nomination and any
supporting data. ATSDR will evaluate data and information associated
with nominated substances and will determine the final list of
substances to be chosen for toxicological profile development.
Public Participation
Interested persons or organizations are invited to participate by
submitting nominations for substances. These
[[Page 53489]]
submissions may include written views and data to support the
nomination. Please note that comments received, including attachments
and other supporting materials, are part of the public record and are
subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your
comment or supporting materials that you consider confidential or
inappropriate for public disclosure. If you include your name, contact
information, or other information that identifies you in the body of
your comments, that information will be on public display. ATSDR will
review all submissions and may choose to redact, or withhold,
submissions containing private or proprietary information such as
Social Security numbers, medical information, inappropriate language,
or duplicate/near duplicate examples of a mass-mail campaign related to
substances being nominated. Do not submit comments by email. ATSDR does
not accept comment by email.
Donata Green,
Acting Associate Director, Office of Policy, Planning and Partnerships,
Agency for Toxic Substances and Disease Registry.
[FR Doc. 2023-16914 Filed 8-7-23; 8:45 am]
BILLING CODE 4163-70-P
